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There is limited evidence on
dose fractionation issues in
adjuvant radiation therapy
(RT) of soft tissue sarcoma.
In this study of 426 patients
from The Scandinavian
Sarcoma Group Register, no
doseeresponse effect of RT
was demonstrated. After
wide margin surgery, 50 Gy
in 25 fractions seemed
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Open access unPurpose: To study the impact of dose fractionation of adjuvant radiation therapy (RT) on local
recurrence (LR) and the relation of LR to radiation fields.
Methods and Materials: LR rates were analyzed in 462 adult patients with soft tissue sarcoma
who underwent surgical excision and adjuvant RT at five Scandinavian sarcoma centers from
1998 to 2009. Medical records were reviewed for dose fractionation parameters and to deter-
mine the location of the LR relative to the radiation portals.
Results: Fifty-five of 462 patients developed a LR (11.9%). Negative prognostic factors
included intralesional surgical margin (hazard ratio [HR]: 7.83, 95% confidence interval [CI]:
3.08-20.0), high malignancy grade (HR: 5.82, 95% CI: 1.31-25.8), age at diagnosis (HR per
10 years: 1.27, 95% CI: 1.03-1.56), and malignant peripheral nerve sheath tumor histological
subtype (HR: 6.66, 95% CI: 2.56-17.3). RT dose was tailored to margin status. No correlation
between RT dose and LR rate was found in multiple Cox regression analysis. The majority
(65%) of LRs occurred within the primary RT volume.
Conclusions: No significant doseeresponse effect of adjuvantRTwas demonstrated. Interestingly,
patients given 45-Gy accelerated RT (1.8 Gy twice daily/2.5 weeks) had the best local outcome.D, Department of Clinical
niversity of Bergen, Jonas
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45 Gy, interposed with
chemotherapy, was feasible
and effective. In addition to
malignancy grade and
surgical margin, histopatho-
logic subtype was associated
with local recurrence.A total dose of 50 Gy in 25 fractions seemed adequate following wide margin surgery. The risk of
LR was associated with histopathologic subtype, which should be included in the treatment
algorithm of adjuvant RT in soft tissue sarcoma.
 2013 Elsevier Inc. Open access under CC BY-NC-SA license.Introduction
Optimal dose fractionation schedule in adjuvant radiation therapy
(RT) in soft tissue sarcoma (STS) of the extremities and trunk wall
is unknown, although a doseeresponse effect of RT has been
reported in some studies (1-4). It is common to recommend at
least 60 Gy postoperatively (daily fractions of 2 Gy) to patients
with high-grade STS, with an additional dose of 6 Gy upto 16 Gy
after positive margin surgery (1, 5-9). In preoperative RT, a total
dose of 45 to 50 Gy is typically prescribed. In contrast, the
Scandinavian Sarcoma Group (SSG) recommendation for post-
operative RT is 50 Gy in 2-Gy daily fractions, plus a boost of 10 to
20 Gy following a positive surgical margin. Accelerated RT with
1.8 Gy twice daily to 36 or 45 Gy, interposed with adjuvant
chemotherapy (CT), has been applied in patients with high-risk
STS (10, 11). Despite differences in postoperative RT doses,
local control rates in series from our institutions compare well
with results from other sarcoma centers (3, 4, 12-17). Although
RT has been increasingly used as adjuvant treatment of STS, we
lack data to guide the choice of RT dose and schedule. Local
recurrences (LRs) still occur, and the majority of these are in field
(15, 18, 19).
This study evaluated SSG RT guidelines and examined the
impact of RT dose fractionation on local control. Tumor-related
factors of prognostic importance were also included in the anal-
yses. Lastly, we performed a retrospective assessment of the
localization of an LR in relation to the RT treatment volume.
Methods and Materials
Ethics
The study was conducted according to the Declaration of Helsinki
and approved by the Regional Committee for Medical Research
Ethics.
Patients and eligibility
From the SSG prospective register, 572 patients from 5 sarcoma
centers (aged 16 years) diagnosed from 1998 to 2009 with
extremity or trunk wall STS who underwent adjuvant RT were
identified. Patients with dermatofibrosarcoma protuberans, Kaposi
sarcoma, extraosseous osteo- and chondrosarcoma, and Ewing
family tumors were not eligible, nor were patients with synchro-
nous metastases. Only the 462 patients who underwent both
primary surgery and RT at a sarcoma center, with complete
recordings of parameters of prognostic importance and follow-up
data, were included in the study (20). Histopathologic tumorclassification and malignancy grading were performed at the
sarcoma centers according to SSG guidelines, Protocol SSG VII:4
(11). Of the 110 patients excluded, 97 had missing data, primarily
because RT was given at a local hospital; 13 patients were
excluded because RT was administered following an LR or with
palliative intent.
Radiation therapy
Details of RT were recorded retrospectively from the
individual radiation charts. Patients were treated primarily with
3-dimensional conformal RT.
According to institutional guidelines, postoperative clinical
target volume (CTV) should encompass the tumor bed including
the affected compartment in the transverse directions and 5 cm
beyond the surgical scar in the longitudinal direction. A 2-cm
margin from the tumor bed in all directions was recommended for
the boost volume. The planning target volume (PTV) typically
encompassed the CTV þ 1 cm setup margin in all directions. In
preoperative RT, the gross tumor volume (GTV) was delineated as
visualized on computer tomography preferably coregistered with
diagnostic magnetic resonance imaging (MRI), using a 2-cm
margin from the GTV to the CTV. The field border was defined by
the 50% isodose curve with a margin of 5 to 8 mm to the PTV
(95% isodose curve). Because PTV delineations were inaccessible
in most cases, we relied on RT simulation images, diagnostic
radiographs, and treating oncologist’s or surgeon’s evaluation
regarding the location of the LR relative to the RT portals. An LR
occurring within the RT portals was classified as in field. If the LR
extended on both sides of the field border, a marginal recurrence
was recorded. If the LR did not involve the RT portal volume, it
was defined as out of field.
Chemotherapy and accelerated RT
The SSG SIN system comprising size (8 cm), vascular invasion,
and necrosis categorizing high-grade STS patients into high- or
low-risk groups, was established in 1998 (11). Grade, surgical
margin, and tumor depth were determinants for RT. High-risk
patients were offered 6 postoperative courses (3-week intervals)
of doxorubicin plus ifosfamide with accelerated RT (1.8 Gy twice
daily at 6-hour intervals to 36 Gy over 2 weeks) interpolated
between the second and third CT course and, if indicated, a split-
course boost (9 Gy/2.5 days, total dose 45 Gy, overall treatment
time 31 days) given between the third and fourth CT course (10).
The biological tumor effect of the increased dose density of the
accelerated regimen and the tight relation to CTwere computed by
modifying the fraction dose by a factor of 1.10 and 1.15,
respectively, assuming an a/b ratio for tumor and acute toxicity of
Table 1 Patient, tumor, and treatment characteristics in 462
STS patients
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patients with high-risk STS also include infiltrative tumor margin
as a risk-stratifying factor (11).Characteristic Value
Age at diagnosis (y) median (range) 61 (16-94)
Tumor size (cm), median (range) 9.0 (1-40)
EQD2 (Gy), median (range) 50 (20-70)
Sex, n (%)
Male 257 (55.6)
Female 205 (44.4)
Tumor site, n (%)
Lower extremity (incl. gluteal) 297 (64.4)
Upper extremity (incl. shoulder) 88 (18.9)
Trunk wall (incl. axillae and groin) 77 (16.7)
Location, n (%)Follow-up and outcome
Follow-up was scheduled at 3-month intervals for the first 2 years
after the completion of treatment, at 6 months during the third and
fourth year, then yearly up to 10 years. Physical examination
and chest radiography were mandatory, with additional MRI when
deemed necessary (tumor area inaccessible for clinical examina-
tion or suspicious findings). The date of (cytologically or histo-
logically verified) distant or locally recurrent disease and cause of
death were reported to the register.Subcutaneous 78 (16.9)
Deep 384 (83.1)
Malignancy grade, n (%)
Low grade (grade 1 and 2) 55 (11.9)
High grade (grade 3 and 4) 407 (88.1)
Histopathologic subtype, n (%)
UPS 181 (39.2)
Liposarcoma 90 (19.5)
Synovial sarcoma 49 (10.6)Analyses
The relation between RT and LR was analyzed with dose as
a categorical variable, grouped by fractionation schedule and total
dose. RT dose, as a continuous variable, was analyzed using
equivalent RT dose to dose in 2 Gy fractions (EQD2) (21). An a/
b ratio of 10 was assumed for tumor effect.Leiomyosarcoma 45 (9.7)
MPNST 26 (5.6)
Other types 71 (15.4)
Number of operations, n (%)
1 439 (95.0)
2 23 (5.0)
Surgical margin, n (%)*
Intralesional 72 (15.6)
Marginal 270 (58.4)
Wide 120 (26.0)
Chemotherapy, n (%)
Adjuvant 142 (30.7)
No chemotherapy 320 (69.3)
Abbreviations: EQD2Z biologically effective radiation therapy dose
equivalent to 2 Gy fractions; incl.Z including; MPNSTZ Malignant
peripheral nerve sheath tumor; STS Z soft tissue sarcoma;
UPSZ Undifferentiated pleomorphic sarcoma.
* IntralesionalZmicro- or macroscopically positive; marginalZ<10
mmcuff of uninvolved tissue;wideZ uninvolved fascia or10mmcuff of
healthy tissue on formalin-fixed specimen.Statistical methods
Descriptive data are given as counts (%), medians, means, and
ranges. Gosset’s independent-sample t test was chosen to compare
distribution of prognostic factors for the dichotomous factor “pre-
or postoperative RT.” Time to LR was computed from the date of
the last operation of the primary tumor. The Kaplan-Meier method
was used to estimate survival curves and the logerank (Mantel-
Cox) test for comparing groups. Univariate analysis by Cox
regression included factors reported in previous studies to have
a prognostic impact on LR. Cox multiple regression with the
likelihood ratio test was used to examine simultaneous effects of
potential prognostic factors for LR and to plot survival curves.
Backward stepwise selection (ie, including all factors in the model
and eliminating the insignificant one by one) was used for
obtaining the final adjusted model. Post hoc analyses for inter-
actions between covariates were performed in the final model.
Competing risk hazard ratios (HRs) for LR were calculated
treating death without LR as a competing event. The most
common category for the categorical covariates and mean values
for continuous covariates were generally chosen in the plots.
A P value .05 was considered statistically significant. Statistical
analysis and data preparation were carried out using the PASW
Statistics 18.0 (SPSS, Chicago, IL) software package and STATA
12 (Statistical package, StataCorp, College Station, TX).Results
Characteristics of the 462 patients are displayed in Table 1. Rare
histopathologic subtypes and undifferentiated STS were grouped
as “other types.” Four-fifths of the patients had not been subjected
to any invasive diagnostics before referral to a sarcoma center, and
only 25 patients (6%) required an incision biopsy for diagnosis at
the center.Radiation therapy
RT was administered postoperatively to 84% (Table 2). The
median time interval between surgery and RT was 64 days in the
postoperative setting and 28 days preoperatively. A higher dose
than 50 Gy was prescribed in only 16% of the cases. Twenty-two
percent of the patients were treated according to one of the SSG
high-risk protocols (10, 11) with postoperative CT and accelerated
RT to 36 Gy (nZ78) or 45 Gy split-course following intralesional
surgery (nZ17) (10). Accelerated 45 Gy was administered as
a continuous (mainly preoperative) course in 9 patients. A minor
proportion of the patients received nonstandard regimens with
hyperfractionation (1.5/1.6 Gy twice daily, nZ5) or moderate
hypofractionation with daily doses of 3 Gy (nZ7). Mean and
median RT doses for the whole study group were 48 and 50 Gy,
Table 2 Distribution of potential prognostic factors among radiation therapy groups in 462 STS patients
Radiation therapy group
All
(nZ462)
< 50 Gy
(nZ38)
36 Gy acc
(nZ78)
45 acc split
(nZ17)
45 Gy acc
(nZ9)
50 Gy/25
(nZ245)
>50-60 Gy
(nZ56)
>60 Gy
(nZ19)
Age, y (mean) 59.4 57.5 52.2 47.1 53.0 63.5 57.1 60.3
Size, cm (mean) 9.9 10.7 10.9 10.9 12.3 9.5 9.8 8.4
Deep location (% ) 83.1 89.5 92.3 88.2 88.9 80.8 78.6 68.4
Trunk location (%) 16.2 23.7 9.0 17.6 11.1 16.7 21.4 10.5
High-grade malignancy (%) 88.1 57.9 100.0 100.0 100.0 89.4 83.9 78.9
Histotype MPNST (%) 5.6 5.3 6.4 17.6 11.1 4.9 5.4 0.0
2 operations (%) 5.0 2.6 3.8 11.8 0.0 6.5 1.8 0.0
Margins
Wide (%) 26.0 31.6 32.1 11.8 55.6 27.8 10.7 10.5
Marginal (%) 58.4 50.0 64.1 35.3 22.2 61.2 60.7 47.4
Intralesional (%) 15.6 18.4 3.8 52.9 22.2 11.0 28.6 42.1
CT given (%) 30.7 21.1 100.0 100.0 66.7 11.4 7.1 5.3
Preoperative RT (%) 16.0 52.6 3.8 0.0 88.9 15.5 8.9 0.0
Abbreviations: acc Z accelerated; CT Z chemotherapy; MPNST: malignant peripheral nerve sheath tumor; split Z split-course; STS Z soft tissue
sarcoma.
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calculated in EQD2.
Three-dimensional planning (including intensity modulated
radiation therapy in some cases) was used in 89% of the patients
and opposing portals in 11%. In 179 cases for which RT volumes
were available, the mean PTV was 1440 cm3. There were no
differences in PTV (PZ.857) or tumor size (PZ.473) between the
group given preoperative RT (nZ27, mean PTV 1476 cm3, mean
tumor size 10.3 cm) and the group undergoing postoperative
treatment (nZ152, mean PTV 1434 cm3, mean tumor size
9.8 cm).
Local recurrence
Median follow-up time was 4.1 years (range 0.1-13.0). Fifty-five
of 462 (11.9%) patients experienced a LR, 9 of whom had >1 LR.
In 49 of 55 (89%) patients, the location of the recurrence in
relation to the irradiated volume could be determined: most LRs
(32/49, 65%) were located within the RT field portals, 10 (20%)
involved the field margin, and 7 (14%) were out of field. The
latter were excluded from the further analyses of RT groups and
prognostic factors for LR. No imbalance was found concerning
prognostic factors and the location of LR. All LRs following the
accelerated 45 Gy split-course regimen (nZ5) or total doses
>60 Gy (nZ2) were in field, in contrast to 4 of 5 (80 %) after
accelerated 36 Gy, 15 of 23 (65.2 %) after 50 Gy, and 5 of 8
(62.5%) after a total dose of >50 to 60 Gy. Subsequent to standard
fractionated doses <50 Gy, 4 of 6 (66.7%) LRs were out of field.
Estimated 5- and 10-year local recurrence rate (LRR) were
13% and 15%, with similar LRRs after preoperative and post-
operative RT. LRRs did not differ between the five SSG centers.
There were significant differences in distribution of risk factors for
LR between the groups given disparate RT schedules (Table 2).
No doseeresponse relationship was found between local
control and RT dose as a continuous variable computed as EQD2.
By grouping RT according to fractionation schedules and total
doses in Gy with 50 Gy/25 fractions as reference dose, the 45-Gy
split-course regimen had a significantly lower local control rate in
the univariate analyses (Table 3). Dose higher than 50 Gy did not
improve local control. When adjusting for additional prognosticfactors, no significant differences were detected between the RT
groups (Table 3).
High age at the time of diagnosis, high malignancy grade, and
intralesional surgical margin were negative prognostic factors for
local control in the fully adjusted Cox regression model and the
final backward stepwise model (Table 3, Fig. 1). Furthermore,
significant differences in LRRs among histopathologic subtypes
were found, with malignant peripheral nerve sheath tumor
(MPNST) displaying the highest risk using the most common
category undifferentiated pleomorphic sarcoma (UPS) as reference
(Table 3, Fig. 2). When applying the competing risk Cox regression
model, the results were similar. The final competing risk model
included the following factors: age (HR: 1.22, PZ.039), malig-
nancy grade (HR: 5.1, PZ.014), histotype (liposarcoma, HR: 2.26,
PZ.043; MPNST, HR: 5.72, PZ.001), and surgical margin
(intralesional vs wide, HR: 6.21, P<.001).
Almost one-third of the patients received CT in accordance
with SSG clinical studies for adjuvant treatment of high-risk STS.
Local control rate was not influenced by CT (Table 3).Discussion
Because of the heterogeneous patient material and risk-tailored RT
administered within a restricted range of doses, in addition to
promising results with accelerated RT to low total doses, we could
not demonstrate a RT doseeresponse effect in STS. Another limi-
tation of our study is that comparisons were performed within
nonrandomized data, illustrated by the fact that the different RT
groups are unbalanced concerning risk factors (Table 2). Further-
more, our analyses on polynomial subgroups entail reduction of the
statistical strength. Hence, subanalyses must be interpreted with the
greatest care. The reliability of the reported surgical margins in our
institutions is, however, high (20). The fraction of patients operated
with intralesional surgical margins predominantly represents
microscopic positive margins because macroscopic intralesional
margins are uncommon following careful treatment planning at
a sarcoma center. The present material comprises tumors with
overall poor prognosis: 81% were >5 cm, 88% high grade, 83%
deep seated, with 71% corresponding to American Joint Committee
Table 3 Potential prognostic factors for local recurrence by simple and multiple Cox regression analysis of 462 STS patients
Factor
Unadjusted models
(nZ462)
Fully adjusted model
(nZ462)
Final backward stepwise
model
(nZ462)
HR 95% CI P* HR 95% CI P HR 95% CI P
Age at diagnosis per 10 y 1.14 (0.96-1.36) .136 1.32 (1.03-1.69) .031 1.27 (1.03-1.56) .025
Sex .784 .638
Male vs female 1.08 (0.61-1.92) 1.56 (0.63-2.12)
Tumor size per 10 cm 1.51 (0.98-2.34) .061 1.23 (0.68-2.23) .501
Tumor depth .217 .382
Deep vs subcutaneous 1.79 (0.71-4.52) 1.54 (0.58-4.06)
Location .852 .459
Trunk vs extremity 0.85 (0.36-2.01) 0.70 (0.28-1.79)
Malignancy grade .063 .025 .021
High vs low 3.83 (0.93-15.8) 6.02 (1.26-28.8) 5.82 (1.31-25.8)
Subgroups histotype .014 .002 .002
UPS 1 reference 1 reference 1 reference
Liposarcoma 1.08 (0.47-2.50) 1.54 (0.62-3.86) 2.04 (0.85-4.90)
Leiomyosarcoma 0.82 (0.24-2.86) 0.67 (0.18-2.51) 0.67 (0.19-2.33)
Synovial sarcoma 1.37 (0.53-3.56) 2.97 (0.92-9.59) 2.15 (0.72-6.40)
MPNST 4.59 (1.92-11.0) 7.91 (2.72-23.0) 6.66 (2.56-17.3)
Other types 1.57 (0.66-3.75) 3.33 (1.23-9.04) 3.15 (1.25-7.97)
Number of operations .333 .444
2 vs 1 0.38 (0.05-2.72) 0.45 (0.06-3.44)
Surgical margin <.001 <.001 <.001
Wide 1 reference 1 reference 1 reference
Marginal 1.52 (0.65-3.56) 1.62 (0.62-4.20) 1.63 (0.67-3.97)
Intralesional 5.86 (2.46-14.0) 7.54 (2.61-21.8) 7.83 (3.08-20.0)
Chemotherapy .528 .494
Yes vs no 1.21 (0.67, 2.21) 1.58 (0.43, 5.84)
Timing of RT .962 .325
Preoperative vs postoperative 0.98 (0.46-2.10) 1.59 (0.63-4.04)
RT groups .046 .357
50 Gy 1 reference 1 reference
< 50 Gy 0.93 (0.28-3.12) 1.13 (0.30-4.25)
36 Gy acc 0.99 (0.40-2.45) 1.93 (0.43-8.70)
45 Gy acc split 4.52 (1.82-11.2) 3.58 (0.75-17.0)
45 Gy acc 1.29 (0.17-9.57) 0.32 (0.03-4.19)
> 50-60 Gy 1.95 (0.89-4.26) 1.80 (0.79-4.08)
> 60 Gy 1.36 (0.32-5.79) 0.78 (0.15-3.91)
EQD2 1.00 (0.96-1.04) .951 - -
Abbreviations: accZ accelerated; acc splitZ accelerated split-course, ie, with treatment gap; CIZ confidence interval; EQD2Z RT dose equivalent
to dose in 2 Gy fractions; HRZ hazard ratio; MPNSTZ malignant peripheral nerve sheath tumor; RTZ radiation therapy; STSZ soft tissue sarcoma;
UPS Z undifferentiated pleomorphic sarcoma.
* From Likelihood ratio test.
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a recent reported series (16).
On the basis of SSG experience that 50 Gy is effective in
completely resected STS (14), a limited number of patients had
received 60 Gy and only a few >60 Gy. This variability was too
small to disclose a doseeresponse effect. In contrast to our find-
ings, a cutoff value of 60 to 64 Gy has been reported in previous
studies demonstrating superior local control with higher dose
levels (1-4). The escalated total doses have usually been motivated
by unfavorable prognostic factors. Although SSG recommend 50
Gy in 25 fractions following marginal or wide surgical margins in
deep-seated high-grade tumors, compared with 60 Gy outside
Scandinavia, LRRs in our institutions are comparable to most
reported findings, suggesting that 50 Gy may be sufficientfollowing wide margin surgery (Fig. 1A) (2-4, 13, 15,17). After
inadequate surgery, there is a rationale for increasing the dose
(Fig. 1B) (1-4). The largest study on RT dose showed improved
local control with RT 64 Gy, in particular, after positive and
uncertain surgical margins (2).
It is interesting that the 45-Gy accelerated group (no split)
displayed the best local outcome in the fully adjusted regression
model, although not statistically significant (Fig. 1). Promising
tumor control with accelerated RT (10) concurs with results from
studies in head and neck cancer (22). Not surprisingly, split-course
RT tends to result in inferior local control compared with
continuous RT regimens (Fig. 1) (22). RT toxicity was not
recorded in the register but has been reviewed and found to be
moderate for the patients undergoing accelerated RT (10).
Fig. 1. Local recurrence-free survival by radiation therapy dose/fractionation and surgical margin, nZ462. (A) Wide surgical margin
(nZ120). (B) Intralesional surgical margin (nZ72). Fully adjusted Cox regression model, mean value for continuous variables (age and
tumor size), and the most common value for the categorical variables (undifferentiated pleomorphic sarcoma histotype, high malignancy
grade, male, deep location, extremity site, one operation, no chemotherapy, postoperative radiation therapy). NS Z not significant.
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the most important prognostic factors for local control (12, 13,
23). Furthermore, the significance of histologic subtype was
demonstrated as MPNSTwas associated with a 35% 5-year risk of
a LR, whereas UPS, liposarcoma, and leiomyosarcoma each had
5-year LRR of approximately 10%. Poor local outcome after
treatment of MPNST has also been reported in previous studiesFig. 2. Local recurrence-free survival by histopathologic
subtype and wide surgical margin, nZ462. Fully adjusted cox
regression model, mean value for continuous variables (age and
tumor size), and the most common value for the categorical vari-
ables (high malignancy grade, male, deep location, extremity site,
one operation, no chemotherapy, postoperative radiation therapy).
MPNSTZ malignant peripheral nerve sheath tumor; STSZ soft
tissue sarcoma; UPSZ undifferentiated pleomorphic sarcoma.of prognostic factors (12, 23). Histologic subtypes represent
a biological diversity that influence radiosensitivity and should be
taken into account in the clinical setting.
The majority of LRs (65%) in our cohort were in field, as in
other reports (18, 19). Princess Margaret Hospital reported on the
geometric relationship between LR (nZ60) and RT volume; 82%
recurred within the target volume and 15% out of field (18).
In 25 cases of STS LRs from the Royal Marsden Hospital, 84% of
LRs arose in target volume I or II (19). Fourteen percent (7/49) of
LRs in our study were out of field. This suggests a too narrow field
border, although target volume designations were similar to
volume definitions presented from Princess Margaret Hospital,
which the authors concluded to be appropriate. Out-of-field LRs
were regarded mainly as instances of uncharacteristic disease
spread or intercompartmental contamination during surgery (18).
One-fifth of LRs in our study arose in the periphery of the PTV,
involving the tissue at the field border receiving 50% of the
prescribed dose. The tumor periphery is believed to hold a high
fraction of clonogenic cancer stem cells, hence, inadequate dose
delivery in the perimeter of the CTV, may explain some of the
local failures.
In conclusion, a total dose of 50 Gy seems adequate following
wide margin surgery, whereas intralesional margins call for
a higher RT dose. Accelerated RT appears to be feasible and
effective in adjuvant RT of STS. Most LRs were in field. Varying
radiosensitivity for diverse histologic subtypes of STS suggests
tailoring the RT dose according to histologic subtype in addition
to grade, size, depth, and the critical factor surgical margin.
Considering the rarity of STS, a multigroup clinical trial could
conceivably shed more light on the optimization of adjuvant RT
dose in STS.References
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